DBV Technologies
DBVT | NASDAQ
$10.27
-$0.75 (-6.76%)
At close: Nov 16, 2026, 4:00 PM ET
$10.27
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 4:10 PM ET
DBV Technologies Company Profile
Company profile explainedCompany Profile
DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults. The company's pipeline also includes Viaskin Milk, currently undergoing Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE)-mediated cow's milk protein allergy, and Viaskin Egg, which is in pre-clinical development for hen's egg allergy. Additionally, DBV Technologies is developing a booster vaccine targeting Bordetella pertussis. Beyond these, the company explores earlier-stage research for a respiratory syncytial virus vaccine and potential therapies for Crohn's disease, celiac disease, and type I diabetes. In partnership with Nestlé Health Science, it is developing MAG1C, a user-friendly atopy patch test for diagnosing non-IgE mediated cow's milk protein allergy in infants and toddlers. DBV Technologies S.A. was established in 2002.
Key Executives
| Name | Position |
|---|---|
| Daniel Tassé | Chief Executive Officer & Director |
| Michele F. Robertson | Chief Legal Officer |
| Virginie Simone Jeanine Verrechia Boucinha | Chief Financial Officer |
| Alan Kerr | Senior Vice President & Head of Global Regulatory Affairs |
| James Briggs | Chief Human Resources Officer |
| Jonathan Neely | VP & Head of Investor Relations |
| Kevin Malobisky | Chief Operations Officer |
| Kevin Trapp | Chief Commercial Officer |
| Pascal Wotling | Chief External Manufacturing & Supply Chain Officer |
| Pharis Mohideen | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 28, 2026 | 8-K | Current Report |
| Oct 28, 2026 | 10-Q | Quarterly Report |
| Sep 30, 2026 | 8-K | Current Report |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 06, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Jul 31, 2026 | 4 | Filing |
| Jul 27, 2026 | S-3ASR | Automatic shelf registration statement of securiti... |
| Jul 16, 2026 | 8-K | Current Report |
| Jul 16, 2026 | 10-Q | Quarterly Report |
| Jun 29, 2026 | 8-K | Current Report |
DBV Technologies
| Country | France |
| IPO Date | Oct 22, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 125 |
| CEO | Daniel Tassé |
Contact Details
BAtiment IRO Châtillon 92320 France
Stock Details
| Ticker Symbol | DBVT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001613780 |
| CUSIP Number | 23306J309 |
| ISIN Number | US23306J3095 |
| SIC Code | 2836 |
Add to Watchlist
Select watchlists to add or remove DBVT